文献速递免疫规划传染病防控与疫情报告

两剂麻疹疫苗有效性随时间推移仍保持高水平:一项法国2017—2019年观察性研究

Two-dose measles vaccine effectiveness remains high over time: A French observational study, 2017-2019.
PubMed 文献 · Vaccine · 2023-08-14

研究分析2017年10月至2019年9月法国麻疹监测系统报告的2—31岁麻疹病例,采用筛查法估计第二剂含麻疹成分疫苗(MCV2)的年龄分层疫苗有效性(VE),并拟合指数衰减模型量化保护随时间下降的速率。结果显示基线分析中VE从2—5岁的99.6%降至26—31岁的91.4%,考虑自然免疫后升至93.2%—99.2%,VE缓慢下降(指数衰减率0.0022/年),接种16年后仍为96.7%。结论支持两剂MCV有效性持续较高,仅轻微衰减。

要点

  • 基线分析中MCV2的VE从2—5岁99.6%降至26—31岁91.4%,考虑自然免疫后升至93.2%—99.2%。
  • VE呈缓慢指数衰减,衰减率0.0022/年,接种16年后VE为96.7%。
  • 研究结果支持实现两剂MCV极高接种覆盖率的重要性。

核心结论

  • 研究证实两剂MCV在免疫数十年后仍保持较高有效性,仅轻微衰减,支持实现两剂MCV极高接种覆盖率的重要性。

研究设计与样本

  • 分析2017年10月至2019年9月法国麻疹监测系统通过强制报告收集的2—31岁麻疹病例数据,采用筛查法估计MCV2年龄分层VE,并纳入自然免疫的四种情景进行改进,另拟合指数衰减模型量化保护下降速率。

主要发现

  • 基线分析(无自然免疫)中VE在各年龄组均较高并随年龄下降,从2—5岁99.6%(95%CI 99.3—99.8)降至26—31岁91.4%(95%CI 85.1—95.0)。
  • 考虑自然免疫后,26—31岁年龄组VE升至93.2%—99.2%,具体取决于情景。
  • VE随时间缓慢下降,指数衰减率为0.0022/年(95%CI 0.0017—0.0028),接种MCV2后16年VE为96.7%(95%CI 96.0—97.4)。
  • 该下降最符合情景2,即26—31岁人群中4.4%为自然免疫且未接种疫苗。

临床怎么用

  • 原文结论支持实现两剂MCV极高接种覆盖率的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: From 2008 to 2019, France has experienced a resurgence of measles epidemics. Surveillance data have shown that the proportion of cases vaccinated with two doses of measles-containing vaccine (MCV) increased with age, raising concerns about the duration of vaccine protection. Our objectives were to investigate age-stratified vaccine effectiveness (VE) for the second dose of MCV (MCV2) and to quantify protection levels over time. METHODS: We analyzed data on measles cases aged 2-31 years, reported via mandatory notification to the French measles surveillance system from October 2017 to September 2019. We estimated an age-stratified VE for MCV2 using the screening method, which compares the vaccination status of cases with that of the general population. We improved this method by accounting for natural immunity, exploring four scenarios with four possible levels of natural immunity in the population. In addition, we quantified the decay rate of protection over time, by fitting an exponential decay model among individuals vaccinated in early life. RESULTS: In the baseline analysis (absence of natural immunity), VE estimates were high in all age groups and decreased with age, from 99.6 % (95 % confidence interval: 99.3-99.8) in 2-5 years old to 91.4 % (85.1-95.0) in 26-31 years old. Accounting for natural immunity increased VE in the older age group to 93.2-99.2 % depending on the scenario. We estimated that VE was slowly decreasing over time, with an exponential decay rate of 0.0022/year (0.0017-0.0028), leading to VE of 96.7 % (96.0-97.4) 16 years after MCV2 vaccination. This decline was most compatible with scenario 2, a scenario of 4.4 % naturally immunized, non-vaccinated individuals in the 26-31 years old. CONCLUSION: Our study confirms the continued high effectiveness of two doses of MCV with only slight degradation, decades after immunization. These findings support the importance of achieving a very high vaccination coverage with 2 doses of MCV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Franconeri L, Antona D, Cauchemez S, et al. Two-dose measles vaccine effectiveness remains high over time: A French observational study, 2017-2019. Vaccine. 2023. PMID: 37586955. doi:10.1016/j.vaccine.2023.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。